iRhythm Zio AT Lawsuit Settlement $45 Million Over Misleading Heart Monitoring Claims
The iRhythm Zio AT Lawsuit Settlement $45 Million Over Misleading Heart Monitoring Claims settlement offers $45M in total, with individual payouts of $1 to eligible claimants who purchased or otherwise acquired irhythm technologies inc. common stock between july 25, 2022 and aug. 9, 2024 (inclusive).. The deadline to file is October 1, 2026. Proof of purchase is required.
Deadline: October 1, 2026
Total amount allocated for all claims
Estimated amount per eligible claim
Submit a completed claim (online or mailed) by the deadline (Oct. 1, 2026) and include: (1) the last four digits of your Social Security number or taxpayer identification number; (2) holdings and transaction details for iRhythm common stock, including shares held at the opening of trading on July 25, 2022, purchase and sale trade dates through Nov. 8, 2024, number of shares purchased/acquired/sold, purchase and sale prices/total amounts, and shares held at the close of trading on Nov. 8, 2024; and (3) supporting documentation such as trade confirmations and/or account statements or broker/financial-institution statements showing both transaction and holding information matching the claim. If submitting on behalf of others, include proof of authority.
Settlement Summary
iRhythm Technologies markets the **Zio AT**—a wearable heart monitoring device that is intended to help detect cardiac issues by sending patient data for review. According to the securities class action, iRhythm and its CEO made **materially false or misleading statements** about key features of the technology during the class period, including how quickly and reliably the device could transmit data, whether it was suitable for **higher-risk patients**, and whether the reported data was **accurate**. Investors alleged that these alleged misstatements artificially increased iRhythm’s stock price, and that when the truth came to light, the price fell—leading to financial losses for people who bought iRhythm common stock between **July 25, 2022, and Aug. 9, 2024**. The lawsuit was filed as a **class action under U.S. securities laws**, seeking damages for investors who traded during that window. Its significance is reflected in the **$45 million settlement**, which resolves claims that the company’s disclosures misled the market; the settlement does **not** necessarily mean the company admitted wrongdoing, but it shows how seriously the federal securities framework treats problems involving investor-facing statements and technology or performance claims. Under the plan described in the notice, eligible investors may receive cash based on a formula tied to “recognized losses” (accounting for when shares were bought and sold), with an estimated average recovery of roughly **$1.83 per eligible share before deductions** and about **$1.34 per share after estimated deductions**—and the size of payouts will depend on how many valid claims are submitted. Broader implications include heightened scrutiny of how medical-device performance and monitoring capabilities are communicated to investors and patients, especially for products that involve ongoing data collection and interpretation. In the background is the wider regulatory environment governing medical devices and cybersecurity/data handling, along with disclosure expectations under the securities laws that require companies to avoid misleading omissions or overstatements about product effectiveness, limitations, and real-world functionality. Similar cases often follow when disputes arise over whether a technology’s advertised capabilities match what was actually delivered or validated, and this settlement fits that familiar pattern—where transparency and accuracy in public statements become central to investor protection and market confidence
Entities Involved
Related Topics
Eligibility Requirements
- Purchased or otherwise acquired iRhythm Technologies Inc. common stock between July 25, 2022 and Aug. 9, 2024 (inclusive).
- Suffered damages as a result of the alleged misstatements (i.e., are part of the settlement class).
- Both individuals and entities may be class members.
- Must be the beneficial owner (record owner is not sufficient) to sign the claim form.
- If there are joint owners, each joint owner must sign the claim form.
- If submitting for others (e.g., agents, executors, administrators, guardians, trustees), must provide proof of authority.
- Holders through an iRhythm employee benefit plan covered by ERISA should not include those plan-held shares on an individual claim form.
- If you have multiple legal entities or separately managed accounts, you must submit separate claims for each.
Featured Investigations
Important Notice About Filing Claims
Submitting false information in a settlement claim is considered perjury and will result in your claim being rejected. Fraudulent claims harm legitimate class members and may result in legal consequences.
If you are unsure about your eligibility for this settlement, please visit the official settlement administrator’s website using the link provided above. Review the eligibility criteria carefully before submitting a claim.
Class Action Champion is an independent information resource and is not affiliated with any settlement administrator, law firm, or court. We provide settlement information as a service to help connect eligible class members with legitimate settlements.